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Drug-resistant human immunodeﬁciency virus type
1 (HIV-1) minority variants increase the risk of vi-
rologic failure for ﬁrst-line nonnucleoside reverse
transcriptase inhibitor (NNRTI)-based regimens.
We performed a pooled analysis to evaluate the rela-
tionship between NNRTI-resistant minority variants
and the likelihood and types of resistance mutations
detected at virologic failure. In multivariable logistic
regression analysis, higher NNRTI minority variant
copy numbers, non-white race, and nevirapine use
were associated with a higher risk of NNRTI resis-
tance at virologic failure. Among participants on
efavirenz, K103N was the most frequently observed
resistance mutation at virologic failure regardless
of the baseline minority variant. However, the
presence of baseline Y181C minority variant was as-
sociated with a higher probability of Y181C detec-
tion after virologic failure. NNRTI regimen choice
and preexisting NNRTI-resistant minority variants
were both associated with the probability and type
of resistance mutations detected after virologic
failure.
Keywords. HIV-1 drug resistance; minority vari-
ants; virologic failure; resistance genotyping.
Human immunodeﬁciency virus (HIV) drug resis-
tance mutations present below 10%–20% of the viral
population are not reliably detected by genotyping
techniques that use population (Sanger) sequencing
[1, 2]. In a recent pooled analysis, we demonstrated
that the presence of baseline drug-resistant minority
variants more than doubles the risk of virologic failure
in patients initiating a ﬁrst-line nonnucleoside reverse
transcriptase inhibitor (NNRTI)-based regimen [3].
However, it is unknown how these baseline minority
variants relate to the risk and type of resistance muta-
tions detected at virologic failure.
The mechanism by which these detectable drug-
resistant minority variants mediate treatment failure
would at ﬁrst glance be straightforward and involve
the expansion of virus harboring that resistance muta-
tion. Such a pattern has been detected in studies of
resistance developing against a CCR5-antagonist [4]
and raltegravir [5]. In addition, there can be a relative-
ly high concordance of preexisting minority variants
with mutations detected after virologic failure of ralte-
gravir-based regimens [6] and NNRTI-based regimens
in treatment-experienced patients [7]. However, these
studies were of limited sample size and data from
treatment-naive individuals do not always support
such a straightforward interpretation [8]. We used
data collected during a previously described pooled
analysis of drug-resistant minority variants to evaluate
the relationship between baseline NNRTI-resistant mi-
nority variants, antiretroviral therapy (ART) regimen,
and other factors on the likelihood and types of
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resistance mutations detected by population sequencing after
virologic failure.
METHODS
This analysis derives from a substudy of a previously reported
pooled analysis of HIV type 1 (HIV-1) drug-resistant minority
variants on the risk of virologic failure for treatment-naive in-
dividuals initiating an NNRTI-based regimen [3]. Patient-level
data were obtained from all studies to exclude participants
with any evidence of pre-ART drug resistance and to stand-
ardize the deﬁnition of virologic failure. A total of 240 partici-
pants are included from seven studies with genotypic
resistance results after virologic failure [8–14].
All of the studies evaluated baseline K103N minority vari-
ants, and 6 of the 7 studies evaluated baseline Y181C minority
variants as well [8–13]. A detailed description of the assays,
limits of detection, and minority variants detected can be
found in the original report [3]. Mutations conferring NRTI
and NNRTI resistance were deﬁned as those with a Stanford
HIV resistance DB score ≥10 for the participant’s ART
regimen. Medication adherence was available from 3 studies
and was determined either by self-reported medication
adherence over the previous 4 [8] or 7 days [9], or by a clinic-
based pill count [14].
Fisher exact tests, Wilcoxon rank sum tests, and Cochran-
Mantel-Haenszel statistics (stratiﬁed by study) were used to
compare factors associated with either the presence of geno-
typing results or resistance at virologic failure. Minority
variant copy number was estimated as the product of percent-
age of minority variant and level of HIV-1 RNA. Individuals
without detectable minority variants were assigned a minority
variant copy number of 0%; in a sensitivity analysis, a minori-
ty variant copy number equivalent to 10% of the assay limit of
detection was imputed. A multivariable logistic regression,
stratiﬁed by study, with backward elimination was performed
to evaluate factors that predicted the risk of NNRTI resistance
at virologic failure. Variables included in the regression model
were determined a priori with the exception of ethnicity,
which was found to be a signiﬁcantly associated with the risk
of NNRTI resistance at virologic failure on univariate analysis.
Statistical analysis and the creation of ﬁgures were performed
using SAS 9.2 and GraphPad Prism 5.
RESULTS
Genotypic resistance data after virologic failure were available
from 240 of the 319 (75%) participants in the original pooled
analysis with virologic failure [3]. The median time from viro-
logic failure to resistance genotyping was 22 days (interquartile
range [IQR], 0–49 days]. More than half of the participants
had NNRTI resistance detected at the time of virologic failure
(Supplementary Table 1). Those with detectable NNRTI resis-
tance at the time of virologic failure had lower baseline CD4+
cell counts (205/mm3 vs 261/mm3, P = .008), and were more
commonly receiving a nevirapine-based regimen (P = .03).
The NRTI component of the ART regimen was variable with
9 different combinations represented. The most common
NRTI backbone used for individuals on either efavirenz or ne-
virapine was zidovudine/lamivudine (AZT/3TC). Of those on
AZT/3TC and efavirenz, 50% (49/99) had detectable NNRTI
resistance at virologic failure compared with 73% (8/11) of
those on AZT/3TC and nevirapine (P = .21). There were sig-
niﬁcant differences in the distribution of races/ethnicities
(P = .003) with whites comprising a smaller proportion of
those with NNRTI resistance at virologic failure than blacks.
Overall mean ART adherence rates were similar between those
with and without NNRTI resistance at virologic failure. No
signiﬁcant differences in baseline characteristics between indi-
viduals with or without resistance testing at virologic failure
were detected with one exception (Supplementary Table 2).
Those without genotyping data had higher rates of ART ad-
herence (P < .01).
A signiﬁcantly higher proportion of those with ≥1%
NNRTI minority variants had detectable NNRTI resistance
at virologic failure compared to either individuals harboring
<1% NNRTI minority variants or no detectable minority var-
iants (92% with ≥1% minority variants vs 49% with <1%,
P = .002 and 92% ≥1% minority variants vs 58% without,
P = .01). A similar outcome was seen when participants were
stratiﬁed based on harboring ≥0.5% vs <0.5% minority
variants. Among those with detectable minority variants at
baseline, increasing copy numbers of NNRTI resistance mu-
tations was associated with a higher probability of resistance
at virologic failure (Figure 1A). Interestingly, individuals with
no detectable minority variants had an intermediate
outcome. This result is likely due to the varying limits of
detection for the assays included in this pooled analysis [3].
Thus, individuals without detectable minority variants based
on a less sensitive assay may, in fact, harbor low-frequency
mutations that might have been detectable by a more sensi-
tive test. We therefore performed a sensitivity analysis using
both measured and imputed minority variant copy number.
Individuals without detectable minority variants were as-
signed an imputed minority variant copy number equivalent
to 10% of the assay limit of detection. Results of this
analysis closely mirrored those of the measured values alone
(Figure 1B).
In multivariable logistic regression analysis, factors
that were independently associated with higher odds of
NNRTI resistance at virologic failure included having a higher
baseline NNRTI minority variant copy number, nevirapine
use, and nonwhite ethnicity (Supplementary Table 3). Baseline
viral load, CD4+ count, and ART adherence were not found to
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be signiﬁcant predictors of NNRTI resistance at virologic
failure.
We evaluated the relationship between the NNRTI-resistant
minority variants detected at baseline and the resistance muta-
tions that emerged at virologic failure. Participants were cate-
gorized into those receiving efavirenz and those receiving a
nevirapine-based regimen. Individuals receiving an efavirenz-
based regimen were found to have K103N as the most
common NNRTI resistance mutation detected at virologic
failure regardless of the baseline resistance pattern (Figure 2A).
However, the presence of baseline Y181C was associated with
a higher rate of Y181C detection at virologic failure (18% vs
3%, P = .01). Y181C was the most commonly detected NNRTI
resistance at virologic failure for those receiving a nevirapine-
based ART regimen, although there were relatively few partici-
pants receiving nevirapine (Figure 2B). In those individuals
with no baseline NNRTI resistance mutation but resistance on
virologic failure, Y181C was detected in 75% (9 of 12) of par-
ticipants receiving nevirapine as compared to 4% (3 of 79) of
those receiving efavirenz (P < .001).
In the original pooled analysis, 228 participants had pre-
ART assessment of minority M184V mutations, and 10 were
found to have an M184V minority variant. Of these 10, viro-
logic failure occurred in 4 participants, and M184V was found
in the virologic failure genotype of 2. By contrast, M184V was
detected by viral genotyping at virologic failure in 21 of 80
participants without preexisting M18V minority variant
(P = .30). The 2 participants with preexisting K65R minority
variants did not have virologic failure.
Figure 2. Association between baseline minority nonnucleoside reverse
transcriptase inhibitor (NNRTI) resistance mutation and the resistance de-
tected by standard genotyping after virologic failure (VF) for those on an
efavirenz-based regimen (A) or nevirapine-based regimen (B ).
Figure 1. Rates of nonnucleoside reverse transcriptase inhibitor
(NNRTI) resistance detected at virologic failure increases with higher
measured copy nos. of NNRTI-resistant minority variants (A) or measured
and imputed copy nos. of NNRTI-resistant minority variants (B ). For
those without detectable minority variants (MVs) at baseline, MV copy
nos. were imputed by using 10% of the assay limit of detection. Abbrevi-
ation: VF, virologic failure.
BRIEF REPORT • JID 2013:207 (15 March) • 895
DISCUSSION
In this study, we found that among treatment-naïve patients
initiating an NNRTI-based regimen, the presence of NNRTI-
resistant minority variants, nonwhite ethnicity, and nevirapine
use were all associated with an increased risk of NNRTI resis-
tance detected at virologic failure. Interestingly, the type of
NNRTI resistance that emerged at virologic failure frequently
differed from those detected as minority variants at baseline.
This ﬁnding was unexpected as the dose-dependent relation-
ship of baseline minority variants with both risk of virologic
failure [3] and detectable resistance at virologic failure initially
suggested a straightforward explanation for their effects. There
are several potential explanations for this discrepancy. The
presence of one minority variant could predispose to the de-
velopment of additional resistance mutations. Despite the rela-
tively short time from the date of virologic failure to resistance
genotyping, there may have been sufﬁcient time since the end
of virologic suppression for selection of more ﬁt resistance
variants [13]. It is possible that earlier virologic sampling in
patients with baseline Y181C minority variant may have de-
tected variants containing both Y181C and K103N prior to
K103N becoming the dominant species. Alternatively, the de-
tection of baseline drug-resistant minority variant could be a
marker of greater underlying viral diversity and may be associ-
ated with the presence of other undetected resistance muta-
tions that eventually become the dominant species.
We found that the type of minority variant mutation at
baseline clearly inﬂuenced which resistance mutations detect-
ed at virologic failure as participants on efavirenz were more
likely to have Y181C detected at virologic failure when that
mutation was present as a baseline minority variant. Which
resistance mutation emerged at virologic failure also was
strongly correlated with the NNRTI regimen. Our results sup-
port the observation both in vitro and in vivo that the Y181C
mutation offers relatively high levels of resistance and ﬁtness
preservation in the setting of nevirapine exposure [15–17].
The same association has been found of the K103N resistance
mutation in the setting of efavirenz use [17, 18].
A number of studies have now shown that nonwhite ethnic-
ity is associated with increased risk of virologic failure [19, 20].
We found that nonwhite ethnicity was also associated with a
higher risk of NNRTI resistance at the time of virologic
failure. One potential explanation may lie in ethnic-speciﬁc
distributions of genetic polymorphisms (eg, in CYP2B6) that
affect antiretroviral medication (ARV) metabolism and drug
concentrations. These genotypes have been shown to affect the
risk of virologic failure and likely affect the risk of resistance
emergence given that slow-metabolizer genotypes are more
frequent in nonwhite participants and allow for longer
periods of functional monotherapy after treatment discontinu-
ation [21].
Due to its low cost, nevirapine continues to be one of the
most commonly used ARVs, especially in developing coun-
tries. In this study, nevirapine use was also independently as-
sociated with a higher risk of NNRTI resistance at the time of
virologic failure. However, this ﬁnding should be interpreted
with caution given the variation in the NRTI backbones,
which could modify the risk of treatment failure and resistance
emergence.
This study has several limitations. First, we combined data
from 7 studies using assays with varying limits of minority
variant detection [3]. We performed a sensitivity analysis
using an imputed proportion of minority variants for those
without detectable minority variants using 10% of the assay
limit of detection. The results were consistent with the analysis
performed using measured minority variant proportion alone.
In addition, one of the studies evaluating an efavirenz-based
regimen did not test for the presence of the Y181C minority
variant [14]. This omission may have led to an underestima-
tion of the association between baseline Y181C minority
variant presence and Y181C detection by standard genotyping
at virologic failure. Finally, only a small proportion of the total
study population was tested for the presence of NRTI resis-
tance, which limits our ability to evaluate the impact of base-
line NRTI-resistant minority variants on their emergence
during treatment failure.
We have now demonstrated that for individuals initiating a
ﬁrst-line NNRTI-based regimen, NNRTI-resistant minority
variants increase both the risk of virologic failure and NNRTI
resistance detection at the time of treatment failure. Our
results also show that the minority variants detected at base-
line frequently differ from the resistance mutations observed
at virologic failure. Additional studies of viral diversity,
linkage analysis of low-frequency resistance mutations, and
longitudinal observations during early virologic failure would
provide further insights on how drug resistance mutations
emerge and evolve during antiretroviral treatment failure.
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